Inflammatory bowel disease patients' willingness to accept medication risk to avoid future disease relapse

American Journal of Gastroenterology

Volumn 110, Issue 12, 2015, Pages 1675-1681

  Bewtra, Meenakshi ^a   Fairchild, Angelyn O ^b   Gilroy, Erin ^a   Leiman, David A ^a   Kerner, Caroline ^a   Johnson, F Reed ^c   Lewis, James D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b RTI HEALTH SOLUTIONS   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; AZATHIOPRINE; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; NATALIZUMAB; TACROLIMUS; GASTROINTESTINAL AGENT; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL ABSCESS; ADULT; ARTICLE; CROHN DISEASE; DISEASE ACTIVITY; FEMALE; HUMAN; INFECTION; INFECTION RISK; INTESTINE FISTULA; INTESTINE STENOSIS; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PATIENT ATTITUDE; PRIORITY JOURNAL; RELAPSE; REMISSION; RISK BENEFIT ANALYSIS; ULCERATIVE COLITIS; ACUTE DISEASE; AGED; COMBINATION DRUG THERAPY; DECISION MAKING; INFLAMMATORY BOWEL DISEASES; MIDDLE AGED; PATIENT PREFERENCE; RECURRENT DISEASE; RISK; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

ACUTE DISEASE; ADULT; AGED; CHOICE BEHAVIOR; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; INFLAMMATORY BOWEL DISEASES; LYMPHOMA; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT PREFERENCE; RECURRENCE; RISK; TIME FACTORS;

EID: 84951567804     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.321     Document Type: Article

References (35)

1. Colombel JF, Sandborn WJ, Reinisch W, et al. Infl iximab, azathioprine, or combination therapy for Crohn,s disease. N Engl J Med 2010; 362: 1383-95
2. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn,s disease. Gastroenterology 2010; 138: 463-8
3. Feagan BG, Lemann M, Befrits R, et al. Recommendations for the treatment of Crohn,s disease with tumor necrosis factor antagonists: An expert consensus report. Infl amm Bowel Dis 2012; 18: 152-60
4. Dhaens G, Van Deventer S, Van Hogezand R, et al. Endoscopic and histological healing with infl iximab anti-Tumor necrosis factor antibodies in Crohn,s disease: A European multicenter trial. Gastroenterology 1999; 116: 1029-34
5. Osterman MT. Mucosal healing in infl ammatory bowel disease. J Clin Gastroenterol 2013; 47: 212-21
6. Modigliani R, Mary JY, Simon JF, et al. Clinical, biological, and endoscopic picture of attacks of Crohn,s disease. Evolution on prednisolone. Groupe d,Etude Therapeutique des Aff ections Inflammatoires Digestives. Gastroenterology 1990; 98: 811-8
7. Cellier C, Sahmoud T, Froguel E, et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn,s disease. A prospective multicentre study of 121 cases. The Groupe d,Etudes Therapeutiques des Aff ections Inflammatoires Digestives. Gut 1994; 35: 231-5
8. Daperno M, Dhaens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn,s disease: the SES-CD. Gastrointest Endosc 2004; 60: 505-12
9. Jones J, Loft us EV Jr, Panaccione R, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn,s disease. Clin Gastroenterol Hepatol 2008; 6: 1218-24
10. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn,s disease (SES-CD than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105: 162-9
11. Truelove SC, Richards WC. Biopsy studies in ulcerative colitis. Br Med J 1956; 1: 1315-8
12. Matts SG. The value of rectal biopsy in the diagnosis of ulcerative colitis. Q J Med 1961; 30: 393-7
13. Dick AP, Holt LP, Dalton ER. Persistence of mucosal abnormality in ulcerative colitis. Gut 1966; 7: 355-60
14. Floren CH, Benoni C, Willen R. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scand J Gastroenterol 1987; 22: 459-62
15. Bewtra M, Kilambi V, Fairchild AO, et al. Patient preferences for surgical versus medical therapy for ulcerative colitis. Infl amm Bowel Dis 2014; 20: 103-14
16. Johnson FR, Ozdemir S, Mansfield C, et al. Crohn,s disease patients, riskbenefi t preferences: serious adverse event risks versus treatment effi cacy. Gastroenterology 2007; 133: 769-79
17. Johnson FR, Ozdemir S, Mansfield C, et al. Are adult patients more tolerant of treatment risks than parents of juvenile patients?. R isk Anal 2 009; 2 9: 1 21- 3 6
18. Johnson FR, Van Houtven G, Ozdemir S, et al. Multiple sclerosis patients, benefi t-risk preferences: serious adverse event risks versus treatment effi cacy. J Neurol 2009; 256: 554-62
19. Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Infl amm Bowel Dis 2008; 14: 1660-6
20. Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infl iximab is associated with improved long-Term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-201
21. Feagan BG, Panaccione R, Sandborn WJ, et al. effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn,s disease: results from the CHARM study. Gastroenterology 2008; 135: 1493-9
22. Regueiro M, Schraut W, Baidoo L, et al. Infl iximab prevents Crohn,s disease recurrence aft er ileal resection. Gastroenterology 2009; 136: 441-50
23. Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health--A checklist: A report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health 2011; 14: 403-13
24. Kanninen BJ. Optimal design for multinomial choice experiments. J Mark Res 2002; 39: 214-27
25. Kuhfeld WF. Research Marketing in SAS: Experimental Design: Effi ciency, Coding, and Choice Designs, SAS 9.2 edition Technical report no. MR-2010C SAS Institute Inc.: Cary, NC, 2010
26. Huber J, Zwerina K. The Importance of utility balance and effi cient choice designs. J Mark Res 1996; 33: 307-17
27. Dey A. Orthogonal Fractional Factorial Designs. John Wiley & Sons: New York, 1985
28. Train KE. Discrete Choice Methods with Simulation Cambridge University Press: Cambridge, 2003
29. Train KE, Sonnier G. Mixed logit with bounded distributions of correlated partworths. In: Alberini A, Scarpa R (eds. Applications of Simulation Methods in Environmental and Resource Economics Springer Publisher: Dordrecht, The Netherlands, 2005, pp 117-34
30. Scott FI, Vajravelu R, Bewtra M, et al. The benefi t to risk balance of combining infl iximab with azathioprine varies with age: A Markov model. Clin Gastroenterol Hepatol 2015; 13: 302-9
31. Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for infl ammatory bowel disease: A prospective observational cohort study. Lancet 2009; 374: 1617-25
32. SEER Stat Fact Sheets: Non-Hodgkin Lymphoma. Available at http://seer. cancer.gov/statfacts/html/nhl.html. Accessed on 24 May 2014
33. Grijalva CG, Chen L, Delzell E, et al. Initiation of tumor necrosis factoralpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011; 306: 2331-9
34. Long MD, Martin C, Sandler RS, et al. Increased risk of pneumonia among patients with infl ammatory bowel disease. Am J Gastroenterol 2013; 108: 240-8
35. West RR, McNabb R, Th ompson AG, et al. Estimating implied rates of discount in healthcare decision-making. Health Technol Assess 2003; 7: 1-60